Always consult your physician before using any peptide or related compound.
SEMAGLUTIDE
What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist — a peptide that mimics the effects of the natural hormone Glucagon-Like Peptide-1 (GLP-1).
Originally developed for type 2 diabetes, it has gained major attention for its metabolic and body-composition benefits in research settings.
How It Works
Semaglutide acts on GLP-1 receptors throughout the body to:
- Suppress appetite and increase satiety
- Regulate blood glucose levels by enhancing insulin release and reducing glucagon
- Slow gastric emptying, leading to a steadier release of nutrients
- Support metabolic balance, improving energy use and fat oxidation
These mechanisms have made Semaglutide a key compound in metabolic and obesity-related research.
Potential Research Benefits
Weight management
Reduced appetite and caloric intake
Blood sugar control
Improved insulin sensitivity and glucose regulation
Cardiovascular support
Favorable impact on lipids and inflammatory markers
Metabolic efficiency
Enhanced fat oxidation and reduced visceral fat
Dosing
Weeks 1–4 0.25 mg once weekly
Starting dose to assess tolerance
Weeks 5–8 0.5 mg once weekly
Early phase appetite modulation
Weeks 9–12 1.0 mg once weekly
Common working range in studies
Weeks 13–16 1.7 mg once weekly
Escalation phase for enhanced results
Weeks 17 2.4 mg once weekly (max studied)
Maximum maintenance dose in research